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Abstract
The term venous thromboembolism refers to various pathological processes among which 
deep vein thrombosis, pulmonary embolism, chronic thromboembolic pulmonary 
hypertension and the thrombotic syndrome. The importance in sports activities is that it 
is a pathology that requires a long recovery period from 3 to 6 months, and a delayed or 
unsuccessful diagnosis can cause a more serious illness or even a fatal outcome. Its 
prevalence in the field of sport is difficult to establish, but empirically it seems to be 
similar to that of the individual who does not practice sport. However, the field of sport 
and its environment offers clinical risk conditions to be taken into account, bruising on 
the vascular bed, rest, travel, dehydration, misguided massage therapy, certain 
medications or a genetic predisposition, may be factors that precipitate their presence. 
This guide updates the process, explains the diagnostic protocol and provides prevention 
guidelines and general treatments, also applied to sport, thinking not only of sport but 
also the professional and accompanying personnel.
© 2015 Consell Català de l’Esport. Generalitat de Catalunya. Published by Elsevier 
España, S.L.U. All rights reserved.
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Guía de práctica clínica para la prevención, diagnóstico y tratamiento  
de la enfermedad tromboembólica venosa en el deporte
Resumen
El término enfermedad tromboembólica venosa se refiere a varios procesos patológicos, 
entre los que destacan la trombosis venosa profunda, el tromboembolismo pulmonar, la 
hipertensión pulmonar tromboembólica crónica y el síndrome postrombótico. La impor-
tancia en nuestro medio reside en que es una patología que precisa un periodo de recu-
peración largo, de 3 a 6 meses, y que un diagnóstico tardío o no bien realizado puede 
ocasionar una enfermedad más grave e incluso un desenlace fatal. Es difícil establecer su 
prevalencia en el ámbito del deporte, aunque de forma empírica parece ser similar a la 
del individuo que no hace deporte. Sin embargo, el ámbito del deporte y su entorno 
ofrece condiciones clínicas de riesgo que pueden ser factores que precipiten su presen-
cia, la contusión sobre el lecho vascular, el reposo de los viajes, la deshidratación, la 
masoterapia mal orientada, ciertas medicaciones o una predisposición genética. La pre-
sente guía ofrece una actualización del proceso, se expone la protocolización diagnósti-
ca, las pautas de prevención y de tratamiento estándar y aplicado al deporte, pensando 
no solo en el deportista sino también en el profesional y en el personal acompañante.
© 2015 Consell Català de l’Esport. Generalitat de Catalunya. Publicado por Elsevier Es-
paña, S.L.U. Todos los derechos reservados.
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Definition
The term venous thromboembolic disease (VTED) covers 
several pathological processes including deep vein throm-
bosis (DVT), pulmonary thromboembolism (PTE), chronic 
thromboembolic pulmonary hypertension and post-throm-
botic syndrome. DVT is the presence of a thrombus in a 
vein, accompanied by a variable inflammatory response. 
PTE is the formation of a thrombus inside a vein and its 
later embolisation in the pulmonary artery, totally or par-
tially blocking it.
In sport, the intrinsic risk of suffering a VTED is similar to 
that of non-athletic individuals. However, athletes are in a 
situation that could result in exposure to unusual or a high-
er number of risk factors such as injuries, travel, immobili-
sation, haemoconcentration, and polycythaemia. The pres-
ence of a genetic hypercoagulability disorder adds a further 
risk1 which can then be extraordinarily increased in indi-
viduals who fraudulently use certain performance enhanc-
ing drugs. On the other hand, thrombophlebitis may be 
brought about by or expedited by various aetiopathogene-
ses associated with direct or indirect injury that is accom-
panied by inflammation of the vessel. The presence of the 
thrombus may be previous to or a consequence of this in-
flammation, always aggravating the clinical profile.
Incidence. The latest reviews indicate that the incidence 
of the first episode of DVT among the general population is 
1.2/1,000 inhabitants/year and it affects 3-5% of the popu-
lation. It is the third cause of cardiovascular death after the 
coronary syndrome and cerebrovascular accidents. The 
mortality of VTED is 14-17% at three months and that of PTE 
is 25% at one week. The morbidity is explained by the recur-
rence of 5-7% of VTED cases at three months; 20% DVT at 5 
years and 23% PTE at 5 years, 17-50% post-thrombotic syn-
drome at one year and 23% at two years, pulmonary arterial 
hypertension recurrence rate of 1 to 5%2 and an incidence 
of severe haemorrhages of 5%3.
Aetiopathogenesis
VTED is a multifactorial and complex disease where the in-
teraction of genetic, estimated at 60%, and environmental 
factors, use of contraceptives, pregnancy, immobilisation 
or cancer, among others, determine the risk of thrombosis 
for each individual4. It is important to stress that genetic 
factors play a very important role and the exposure to pro-
thrombotic environmental factors will trigger appearance 
of the event. 
The known genetic factors are deficiencies in anti-
thrombin-III, protein C and protein S (natural anticoagu-
lants of the blood coagulation cascade), Factor V Leiden 
mutation and the G20210A mutation in prothrombin or F-II 
gene. Over the last few years this list has been extended 
and at present there is solid scientific evidence showing 
the implication of other genetic disorders in the risk of 
thrombosis5. Based on this scientific evidence, it is essen-
tial to evaluate the presence of prothrombotic genetic 
factors when assessing the risk of thrombosis in an ath-
lete. This is then especially important if they present a 
personal or family history of venous thromboembolic dis-
ease. The integration of clinical and genetic data provides 
more information for more efficient and personalised di-
agnosis, treatment and prevention of thromboembolic dis-
ease.
The pathogenicity and development of DVT involves 
three factors known as Virchow’s triad: injury to the vein 
wall, venous stasis and hypercoagulability. Damage to the 
endothelium means that it loses its capacity to inhibit co-
agulation and initiate the fibrinolytic process. Stasis due 
to immobilisation or vein obstruction inhibits the clear-
ance and dilution of activated coagulation factors. Final-
ly, the congenital or acquired thrombophilic conditions 
promote the thrombotic process6,7. The factors that may 
simplify the appearance of transitory DVT are shown in 
Table 1.
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Classification
DVT of lower extremities is classified according to its loca-
tion as:
Distal
Including: Calf veins (gastrocnemius), tibioperoneal trunk 
(posterior tibial and peroneal veins), anterior tibial veins 
and soleal veins.
Asymptomatic in 75% of cases.
Only 5% give rise to PTE or post-thrombotic syndrome.
Without treatment, 20-30% progress into proximal areas.
Proximal
Including: External iliac vein, internal iliac vein, common 
femoral vein, deep femoral, superficial femoral, and popli-
teal veins.
90% of PTEs are caused by emboli from proximal DVT.
Diagnosis
This is usually through risk assessment, clinical examination 
and complementary tests8.
Risk assessment 
The probability of diagnosing DVT is established by the 
Wells model for proximal thrombosis9-11 (Table 2).
There is a classification of risk factors for active athletes 
that combines those intrinsic to their activity with those 
related to their quality of physically active individual (Table 
3). The genetic risk in patients and family members with a 
risk of suffering thromboembolic events was studied by con-
sidering the factors mentioned in Table 45,12.
Clinical assessment
The main signs of inflammation are tumour, rubor, heat and 
pain. Pain is usually the first symptom. Of insidious or spon-
taneous onset and with a sensation of heaviness or tension 
in the extremity, it is often accompanied by functional dif-
ficulty. The location varies depending on the affected area. 
In the case of the lower limbs, it usually appears in the calf 
region and along deep vein pathways (hollow of the knee, 
Hunter’s canal, and groin). Homans’ sign (forceful dorsiflex-
ion of the foot with the knee straight causes pain in the calf 
and hollow of the knee) only appears in one third of DVT 
cases, and more than 50% of patients do not show this sign, 
or it exists without the process5,13.
The oedema is initially soft and with fovea, affecting re-
gions distal to the venous obstruction. Palpating the mus-
cle, especially the calves, reveals a characteristic indura-
tion. This hardening should not be confused with oedema of 
subcutaneous cell tissue typical of other affectations not 
related to venous disease.
The increased superficial venous network that gradually 
forms as a result of a mechanism to compensate venous 
drainage and although it may not be appreciated in the very 
Table 1 Trigger factors for transitory or acquired venous 
thromboembolic disease
Estimated risk
Major trigger factors
 Immobilisation with plaster cast 36.5
 Major orthopaedic surgery 16.2
 General surgery 9.5
 Severe injury 4.8-8.6
 Being bedridden 5.6
 Autoimmune disease (bout) 3.9-16.4
 Pregnancy and postpartum period 4.3
Minor trigger factors
 Long trip of more than 5 hours 2.8
 Intake NSAIDs 2.5
 Obesity 2.3
 Cancer 1.8-2.2
 Infections 1.7-2.7
 Admission to hospital 1.9
 Any serious illness 1.7
 Anti-psychotic drugs 1.5-1.8
 Chronic kidney failure 1.6-1.9
 Negroid 1.6
 Environmental pollution 1.5
 Tamoxifen / Raloxifene 1.5
 COPD 1.4-1.6
 Varicose veins 1.4
 Diabetes mellitus 1.4
 Congestive heart failure 1.4
 Oral contraceptives 1.3
 Tobacco addiction 1.1-1.5
 Hormone replacement therapy 1.2
The estimated risk is reported as a hazard ratio, relative risk 
or odds ratio. All of them are considered equivalent44.
Deficient hydration favours any of the above criteria45,46.
Table 2 Probability of the diagnosis of DVT. Wells’ cri-
teria
Paralysis, paresis or recent immobilisation of the 
lower extremities in a plaster cast
+1
Bedridden > 3 days or major surgery with general or 
local anaesthetic in the last 12 weeks
+1
General swelling of the leg +1
Unilateral increase of the calf diameter > 3 cm 
(measured 10 cm below the tibial tuberosity)
+1
Tenderness along line of femoral or popliteal veins +1
Pitting oedema limited to the symptomatic leg +1
Dilated collateral superficial veins (non-varicose) +1
Malignancy (including treatment up to six months 
previously)
+1
Alternative diagnosis as more likely than DVT −2
Clinical probability high if ≥ 3, moderate if 1-2, and low 
if = 0.
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early phases of thrombosis, may be a clear sign in proximal 
or somewhat more evolved thrombosis.
As the signs and symptoms are not very specific, and may 
refer to other acute or chronic affections such as a torn 
muscle, cellulitis, lymphoedema, certain neurological pro-
cesses, etc. A careful case history and examination should 
be worked up accompanied by other methods to simplify 
diagnosis. 
Complementary tests
1. Echo-doppler of the lower limbs. The technique of choice 
for suspected proximal DVT, offering high-sensitivity and 
specificity in symptomatic patients. Its sensitivity is re-
duced in distal DVT and in asymptomatic patients, its effi-
cacy being less than ideal in patients with distal, pelvic or 
recurrent thrombosis.
2. Basic analysis with blood count, biochemistry and co-
agulation tests determining D-Dimer. In this case, normal is 
considered to be below 500 ng/ml14. Studies of its power as 
an analytical marker of VTED concluded that it has high 
sensitivity (98-100%) and low specificity (35-39%)15. If this is 
combined with the negative predictive value that could be 
98%, this test becomes a useful tool for exclusion diagnosis 
of DVT, but not for establishing it. For this reason it is a 
variable forming part of the diagnostic algorithms used at 
present16 but which has no value in itself. D-Dimer is exclu-
sively generated by the degradation of stabilised fibrin, 
whereas fibrinogen degradation products (FDP) may origi-
nate from degradation of fibrinogen or destabilised fibrin; 
the latter producing monomeric D fragments but never D-
Dimer17. For this reason, D-Dimer is a specific marker of fi-
brinolytic activity in processes with excessive fibrin forma-
tion. However, other pathological processes that are not 
thrombotic may also cause elevation of D-Dimer18. Possible 
false negatives. However, it has a lower predictive value of 
around 85% in patients with distal or infrapopliteal throm-
bosis, thrombosis of more than 1 week of progress (the fig-
ures may become normal), anticoagulated patients, distal 
thrombosis and pulmonary embolism in subsegmental arter-
Table 3 Classification of VTED risk factors (adapted from the PRETEMED Guide) and their possible appearance in active athle-
tes
Factor Sport Factor Sport
Physical Acute clinical conditions
 Pregnancy  CVA with lower limb paresis
 Age  Dehydration Yes
 Postpartum  AMI
Life style  Severe acute infection Possible
 Bedridden/immobilised Accidental  Heart failure
 Smoker Possible  Injury to lower limb Yes
 Plane travel (> 6 hours) Yes Chronic clinical conditions
Drugs and surgery  Diabetes mellitus Possible/NL
 Oral contraceptives Feminine  Inflammatory intestinal disease Possible/NL
 Anti-depressants Possible/NL  Severe decompensated COPD
 Antipsychotic drugs  Hyperhomocysteinemia
 Central venous catheter  HIV Infection Possible
 Erythropoietin  Multiple myeloma
 Aromatase inhibitors Possible/NL  Nephrotic syndrome
 Pacemaker Possible/NL  Neoplasias Possible
 Tamoxifen/ Raloxifene  Obesity (BMI > 30) Possible
 Hormone replacement therapy  Thrombophiliaa Possible
 Previous DVT Possible
 Vasculitis Possible/NL
a Genetic risk factors are identified in 87% of patients with thrombosis.
Yes: indicates this factor may be present; Possible/NL: indicates that its presence is possible but not likely.
Table 4 Indications for VTED risk assessment by genetic 
susceptibility study. Thromboincode®
Patients with VTED pattern
Patients in an environmental risk situation for 
thrombosis
Family members of patients with a family history of VTED
Disease suggesting a hereditary component
 Idiopathic venous thromboembolism in < 45 years
 Recurrent venous thrombosis
 Venous thrombosis in uncommon vascular areas
 Neonatal purpura fulminans
 Warfarin induced skin necrosis
 Fetal loss or spontaneous miscarriages
 Venous thrombosis in pregnant women
 Venous thrombosis in women taking contraceptives
 Unexplained arterial thrombosis 
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ies. Elevated D-Dimer values will never be sufficient to di-
agnose VTED. The D-Dimer value is also used to determine 
the progress of the process19,20.
3. ECG and Chest Rx.
4. Angio-magnetic resonance imaging. A non-invasive 
thromboembolism diagnostic method with a sensitivity and 
specificity comparable to phlebography in pelvic and femo-
ral vein thrombosis, offering the possibility of a combined 
examination of the lower limbs and the respiratory system. 
Useful in patients with plaster casts, during pregnancy and 
in patients allergic to the iodinated contrast phlebography 
requires. 
5. Computerised axial tomography (CAT scan). A CAT scan 
with contrast is also a useful test for diagnosing proximal 
DVT. It allows assessing the location of a previously placed 
vena cava filter if necessary. In the case of suspected PTE 
the most suitable procedure is to initially perform an angio-
pulmonary CAT scan because of its proven high sensitivity in 
the diagnosis of pulmonary embolism compared to angiog-
raphy and ventilation-perfusion scintigraphy.
6. Determination of the genetic susceptibility. This de-
termination explains 60% of VTED cases. The presence of 
any of the indications shown in table 4 justifies its evalua-
tion.
Algorithm for therapeutic DVT diagnosis 
(Figures 1 & 2)
The accessibility to ultrasound scans in the field of sport 
enables accelerating the diagnostic process and so risk 
evaluation and Echo-doppler can be performed quickly in 
the event of clinical suspicion while requesting a D-Dimer 
determination. On the other hand, it may even be immedi-
ate if adequate technology is available. The presence of D-
Dimer will only corroborate the previous diagnosis by Dop-
pler Ultrasonography or will provide information about the 
progress of the process.
Echo-doppler21
This ultrasound imaging technique has become the initial 
and main diagnostic test for the diagnosis of DVT due to its 
high-sensitivity and specificity, especially in the proximal 
venous sector. The most direct and reliable sign is the impos-
sibility of complete collapse of the vein walls when com-
pressed with the echographic probe in cross-sectional pro-
jection. On occasions it is possible to directly view the 
texture of the intraluminal thrombus and subjectively deter-
mine the age of the thrombus by its degree of echogenicity; 
the higher the echogenicity, the older the thrombus. 
The reliability of the echo-doppler in diagnosis of DVT 
when dealing with proximal venous sectors (femoral and 
popliteal veins and large proximal veins of the soleus and 
gastrocnemius) offers high sensitivity (96%) and specificity 
(98%). However, when the DVT is limited to the plexus so-
leus and gastrocnemius veins the sensitivity is reduced 
(73%)22. This low sensitivity in the distal sector means re-
peating the ultrasound scan one week later whenever it is 
negative and the clinical suspicion high23. 
In any examination of medial and distal segments of the 
plexus soleus and gastrocnemius it is impossible to ensure 
complete collapse of the wall of each and every soleal-calf 
vein. This is mainly due to the small calibre of the veins at 
this level and the difficulty to detect complete compress-
ibility as a direct sign of the presence of a thrombus. Under 
these circumstances the experience of the examiner be-
comes extremely important, as does the optimisation of 
every echo-doppler unit with slow flow rates, the system-
atic comparison with the asymptomatic contralateral ex-
tremity, manoeuvres to effectively increase the flow 
through expression of the footpad with the extremity in-
clined, the detection of colour irrespective of the examina-
tion angle of the echographic probe (angio or power-dop-
pler) or the selective use of echocontrasts.
Indirect signs of normality are the existence of spontane-
ous flow or variation of the flow in relation to movements 
of the diaphragm. These are detectable by B colour mode 
or doppler spectrum. However, it is only possible to detect 
them in large diameter veins such as the femoral veins or 
the ileus-caval venous system. In more distal sectors it is 
necessary to assess the permeability of the plantar or sole-
al-calf venous plexus by manual compression or by using a 
sleeve.
The echographic signs that will help differentiate chronic 
and acute situations are:
• The vein does not fully collapse and it has a normal 
diameter, unlike what occurs in acute DVT when the diam-
eter is larger.
• The vein walls can be seen as swollen and poorly de-
fined.
• The thrombotic material inside the vein is not echolu-
cent or homogeneous as occurs in acute DVT.
• There are often replacement venous systems in the 
area around the totally or partially occluded vein, with de-
velopment of collateral venous circulation through unusual 
anatomical spaces.
• There are veins with partial occupation of their lumen 
showing valvular insufficiency to venous reflux challenges.
• There is an echo-doppler examination report of a previ-
ous acute episode that can be compared to the current ex-
amination.
The echo-doppler report for an examination of suspected 
acute DVT should indicate:
• Whether the absence of collapse of the vein wall is 
complete or partial.
• Whether the diameter of the vein is increased com-
pared to the contralateral extremity.
• Define the vein sector affected by the thrombosis and 
its proximal and distal extension.
• Define the echographic characteristics of the thrombus 
(echolucent or echogenic).
However, remember that the clinical criteria of Wells’ 
risk stratification, together with the determination of D-
Dimer, enable good diagnostic efficacy for DVT of the lower 
extremities in Emergency Rooms. In the event of low clini-
cal probability with D-Dimer negative, the performance of 
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Doppler Ultrasonography is unnecessary as it can be as-
sumed to be negative for the diagnosis of DVT in the lower 
extremities24 (Figure 2)
Complications 
Pulmonary thromboembolism
The greatest complication is a PTE and this may occur from 
important veins such as those in the legs, pelvis, abdomen, 
arms or neck. The annual incidence of PTE is 0.1%; ranging 
between 0.01% in young adults up to 1% in the over 60 age 
group, and causes de high morbidity and mortality25,26. More 
than half of these events originate as DVT. On the other 
hand, we are faced with a situation with high mortality de-
rived from underdiagnosis. Only one of every three deaths 
from pulmonary embolism is diagnosed before death, and 
when this occurs and the condition is treated adequately, 
the mortality rate drops considerably. It should be taken into 
consideration in the event of any important bruising in these 
regions and appearance of symptoms indicating the process. 
PTE may only appear with dyspnoea and/or tachypnoea at 
rest or slight effort, sometimes in addition to tachycardia 
and in some cases chest pain and/or haemoptysis.
Recurrence of DVT
Patients who are anticoagulated for brief periods (6 to 12 
weeks) for uncomplicated calf DVT have a 20% risk of pro-
gression of the thrombus to proximal DVT. The risk of re-
currence is 8 to 30%, and that of developing post-throm-
botic syndrome 1.8 to 20%. Long term oral anticoagulation 
implies a risk of severe haemorrhage of up to 5% annually 
(Khan 2015). This type of anticoagulation to prevent re-
Suspected DVT
Clinical assessment
 Wells Scale
Low probability
< 2
Moderate/high
≥   2
Not elevated Elevated
D-Dimer
Echo-doppler
+–
No DTP DTPconfirmed
Eco doppler
+ –
D-Dimer
Elevate Not elevated  
Eco doppler
in one week
+ –
No DTV
Personal or family 
history of VTED
Genetic test
+–
Preventive and
therapeutic measures
Figure 1 DVT diagnostic algorithm in the athlete. The accessibility of Ultrasonographic diagnosis facilitates the application of this 
technique in an early stage. Sport physician must familiarize with the exploration of the vascular territory for this purpose. 
Suspected
Compressible
Bilateral selective Echo-doppler Compressibility 3 
femoral and popliteal veins and veins 
proximal to the soleal and calf veins
Not compressible
Treatment
Other causes
justify the clinical 
signs?
Repeat bilateral
selective Echo-doppler
at 7-10 days
Confirmed DTV
Initiate 
Anticoagulatio
Asses the iliac cava
examination
Compressible Not compressible
DISCHARG Anticoagulatio
Always Wells Scale ≥ 2 or if dímer-D +
* The options to repeat the Echo-doppler at one week depend on clinical and analytical 
criteria or always repeat it. In the context of sport apart from determining 
the clinical risk and D-Dimer, it should always be repeated.
Sí
No
Figure 2 Evaluation of suspected DVT in ambulatory medicine.
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currence should be considered in patients with a previous 
history of thrombosis or congenital or acquired suscepti-
bility.
Treatment
The treatment will depend on the diagnostic indications 
and combined with pharmacological anticoagulation and 
general measures27.
Superficial vein thrombosis or thrombophlebitis
• Hospital admission not required, although it may be rec-
ommended in recurrent cases to dismiss Trousseau’s syn-
drome (migratory thrombophlebitis associated with neo-
plastic processes).
• Low molecular weight heparin (LMWH): 
— Without affectation of the saphenous arch (Clexane 
40 mg, Fragmin 5,000 IU, Hibor 3,500 IU, Innohep 4500, all 
every 24 hours with a minimum duration of 7-10 days.
— In the event of affectation of the saphenous arch, 
3 months anticoagulation is recommended and an appoint-
ment with a haematologist.
• Analgesia.
• Relative rest.
• Use of graduated elastic compression stockings.
Confirmed deep vein thrombosis
• Outpatient treatment except for the reasons shown in 
Tables 5-7.
• Prescribe VKA (vitamin K antagonist) with INR therapeu-
tic interval between 2-3; new oral anticoagulants (NOACs) 
or LMWH adjusted to the patient›s weight (Table 8)28,29.
• Use of compression stockings to the root of the affect-
ed limb, avoiding excessive compression and varying it de-
pending on the progress of the oedema30.
• Analgesia.
• Active mobilisation of the affected extremity should be 
initiated as soon as possible. Rest should be relative as of 
the first day of hospitalisation: although the need has not 
been demonstrated, it should be adjusted depending on the 
pain and oedema (adjust days depending on the stage of the 
thrombus as determined by a specialist in Echo-doppler). 
• When beginning activity: (i) protect the individual from 
direct or indirect injuries that require a level of haemosta-
sis within normal limits; (ii) prevent high intensity isometric 
exercises of the affected extremity or any that require a 
considerable increase diaphragm pressure; (iii) determine 
the degree of activity depending on the recovery process as 
determined by additional tests (Dimer D, thrombus quality) 
and the anticoagulation level and associated aspects that 
characterise normal physical activity. Table 9 shows the 
standard recommendations in this regard until considered 
fit to compete31.
Duration of the treatment
In patients with a transient trigger (Table 1) recurrence is low-
er (3%), compared to a spontaneous event (10%). Treatment 
over 3 months with vitamin K antagonist (VKA), NOACs or 
LMWH reduces the risk of recurrence by 90%. In patients with 
greater risk factors, such as surgery, the risk of recurrence is 
< 3% and so treatment can be suspended after 3 months. In 
moderate patients, the risk is somewhat higher (5%), and so 
consideration should be given to maintaining treatment up to 
6 months as the risk of haemorrhage is 2% at one year.
That is, in an athlete who presents VTED treatment 
should be maintained for at least 3 months and consider-
ation given to duration of up to 6 months.
Table 5 Exclusion criteria for outpatient treatment
Exclusion criteria
Absolute Lack of collaboration or follow-up difficulties
Intense pain
Patients with suspected severe underlying 
illness or malignancy
High risk of haemorrhage: Malignant HBP, 
peptic ulcer, recent surgery, altered 
coagulation, thrombocytopenia
Phlegmasia cerulea or alba dolens
Severe illness requiring hospitalisation
Relative Patients without clear diagnosis
Suspected pulmonary embolism
Suspected rapid progression or thrombosis  
of the inferior vena cava
Post-thrombotic syndrome
Allergy, contraindication or limitations on 
the use of low molecular weight heparin: 
Thrombocytopenia, morbid obesity
PTE relapse
Fibrinolytic treatment
Pregnant women
Risk of recurrent DVT (previous DVT, 
pregnancy)
Bilateral DVT
Table 6 Contraindications for anticoagulation
Absolute Relative
Severe active haemorrhage Imminent or recent surgery
Recent intracranial 
haemorrhage
Serious injury
Severe uncontrolled HBP Recent birth
Dissecting aortic or cerebral 
aneurysm
Severe anaemia
Uncorrected coagulation 
disorders
Active ulcerous disease. 
Pericarditis or pericardial 
effusion
Pericarditis o vessament 
pericàrdic
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Prevention
Calculation of the probability  
of a correct diagnosis (Table 2)
In low risk patients: No special measures.
Patients at risk of VTED: LMWH at preventive doses, or 
thrombin and factor Xa inhibitors or vitamin K antagonists.
In athletes the decision to use LMWH or NOACs will de-
pend on the experience of the medical team and the type 
of sport played. Table 10 shows the concepts in relation to 
the possible use of one or another and the interactions with 
certain treatments or nutrients are shown in Table 11.
For example: With NOACs, any sporting activity with an ad-
versary or the possibility even though remote of a bruise, ad-
vise against performing this activity. With LMWH one adminis-
tration at night permits morning training with guarantees, as 
does administration in the morning for evening training.
General measures and evidence level  
(Table 12)
Activity
Immobility increases the risk of DVT 10 fold32. The mobility 
of the muscles of the lower limb should be stimulated to 
prevent the formation of thrombi. Leg exercises reduce ve-
nostasis and should be recommended (Evidence I and II-1). 
This requires:
• Walking. When travelling by plane or train, walk for at 
least five minutes every hour along the aisles of the plane 
Table 7 Criteria for anticoagulation in outpatient 
treatment
LMWH NOACs
Administration Subcutaneous Oral
Treatment 
adherence
Adequate with risk Good
Anticoagulation 
level
Good Good
Half-life ½ to 3 h 12 h
Duration of action Up to 12 h > 24 h
Antidote Yes (protamine) No
Risk haemorrhage 
bruising-certain 
sporting activities
Low and controlled 
with suitable 
doses
Exists. No 
activity with 
contact or risk 
of collision is 
recommended
Possible minor 
surgery in ICU
Yes Complicated
Contraindications Table 8 Table 8
Pharmacological 
interactions
PG synthesis 
inhibitors and 
antiplatelet 
agents
Table 11
Table 9 Reference model until considered fit to compete 
after initiating anticoagulation
Week 1 to 3 Progressive return to everyday life
Week 4 Initiate activities without load (e.g. 
swimming)
Week 5 Initiate exercises without impact 
(closed chain)a
≥ 6 weeks Initiate the exercises with impact (open 
chain)b
a Bicycle, ergometric exercises.
c Jogging, skipping, games…
Adapted of Partsch & Blättler30.
Table 8 Pharmacological measures for the prevention of DVT
Generic name Trade name Dose/day Contraindications
LMWH
 Bemiparin Hibor® 3,500 U (0,2 ml)/24 h Allergy, thrombocytopenia, 
haemorrhages
 Dalteparin Fragmin®, Boxol® 5,000 U/24 h
 Enoxaparin Clexane®, Decipar® 40 mg (0,4 ml)/24 h
 Nadroparin Fraxiparina® 3,800 U (0,4 ml) < 70 kg U 
(0.6 ml) > 70 kg
 Tinzaparin Innohep® 3,500 U (0.35 ml) < 70 kg U 
(0.45 ml) > 70 kg
Indirect factor Xa inhibitors
 Fondaparinux Arixtra® 2,5 mg Allergy, active haemorrhage, 
acute bacterial endocarditis, 
severe acute kidney failure
NOACs
 Table 10
DVT: deep vein thrombosis; LMWH low molecular weight heparin.
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Intermittent pneumatic compression (IPC) (pre- and 
post-surgery). Not described in this review.
Mechanical pumps for the feet (pre- and post-surgery). 
Not described in this review.
Prevention of VTED in sport
Patient. The athlete and companions with clinical condi-
tions of risk applied to the field of sport, should include the 
presence of genetic factors as a risk condition (Table 13).
Consideration. The athlete may suffer important injuries 
that compromise venous flow to a greater or lesser degree 
and trigger an inflammatory process in the vessel with the 
Table 10 Indications for new oral anticoagulants (NOACs) approved by the European Medicines Agency in adult individuals 
without impaired renal function or haemorrhagic risk
Dabigatran  
Pradaxa®
Rivaroxaban  
Xarelto®
Apixaban Eliquis®
Prevention of venous thromboembolism  
in scheduled orthopaedic surgery
Initial dose  
of 110 mg  
and then 220 mg/24 h 
10 mg/24 h 2.5 mg/12 h
Treatment of deep vein thrombosis (DVT)  
and pulmonary embolism (PE), and prevention of 
DVT and PE relapse in adult patients
150 mg/12 h 15 mg/12 h 3 weeks, 
then 20 mg/24 h 
5 mg/12 h
Prevention of stroke and systemic embolism in 
patients with atrial fibrillation
150 mg/12 h 20 mg/24 h 5 mg/12 h
Source: Mateo28.
Table 11 Pharmacological interactions of NOACs applica-
ble to the three in general
Reduce the effect Attitude
Rifampicin, St. John’s wort 
(Hypericum), 
Carbamazepine, Phenytoin
No associar
Increase the effect Actitud
Azole antimycotics  
(ketoconazole,  
itraconazole,  
voriconazole,  
posaconazole)
Do not associate
HIV protease inhibitors 
(ritonavir and similar)
Do not associate
Anticoagulant drugs Do not associate
Macrolide antibiotics 
(Erythromycin, 
Clarithromycin)
Precautions
NSAID Precautions
Acetylsalicylic acid  
or clopidogrel
Precaution. Increase risk 
of bleeding
Quinidine Precautions
Amiodarone Precautions
Verapamil Reduce dose
Source: Mateo28.
or carriage. When travelling by car or coach, stop every 
hour and take advantage of the opportunity to walk.
• If the sitting position must be maintained, an attempt 
should be made to activate the muscles. Bend the knees, 
move the feet by flexing, stretching or rotations, press the 
feet progressively against the floor, alternating one, the 
other, and both at the same time.
Hydration
Haemoconcentration increases the viscosity of the blood 
and reduces flow, especially in the deep veins in the legs of 
immobile patients33,34, good hydration should be ensured 
(Evidence II-3).
Mechanical methods
Mechanical methods that ensure passive mobilisation of the 
lower limbs, imitate muscle contractions and increase the 
venous flow volume and speed35.
• Graduated elastic compression stockings (GECS) (8-18 
mmHg).
• Intermittent pneumatic compression (IPC) (pre- and 
post-surgery).
• Mechanical pumps for the feet (pre- and post-surgery).
Mechanical methods are indicated in patients with in-
creased risk of bleeding, thus making pharmacological pre-
vention hazardous. They are contraindicated in patients 
with a risk of ischaemic skin necrosis or peripheral neuropa-
thy.
Graduated elastic compression stockings (GECS). A meta-
analysis of randomised controlled studies of DVT preven-
tion36 found that it occurred in 8.6% of patients treated 
compared to 27% of controls (OR 0.34; 95% CI 0.25, 0.46)12, 
and so GECS can be said to be effective in the prevention of 
DVT in surgical patients (Evidence I) with stockings up to 
above knee height being preferred. The effectiveness of 
GECS increases significantly when combined with pharma-
cological prevention (Evidence I).
One multicentric observational study found that the 
combined method is more effective that pharmacological 
prevention alone37 (Evidence II).
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consequent procoagulant alteration limiting anticoagulant 
activity. These affections may be of certain importance on 
musculotendinous tissue and blood vessels of the area, espe-
cially if they occur on the leg, ankle or foot as on many oc-
casions they require immobilisation and a certain period of 
rest. Up to 34% of Achilles tendon ruptures result in DVT, ir-
respective of whether they are operated on or not38. In oth-
er cases the need for surgical, diagnostic or remedial tests 
for example in knee arthroplasty, the guidelines for surgical 
prevention provide limited practical orientation as, depend-
ing on the series presented, the prevalence covers a very 
wide range and it is not clear how to transfer the results of 
randomised studies into clinical practice, as a large number 
of cases de VTEDs are luckily limited by routine prevention 
when available and are asymptomatic distal DVT. Therefore, 
there is no consensus regarding the real application of phar-
macological prevention actions, and so patients subjected 
to knee arthroscopy should be managed on an individual de-
cision based on VTED risk assessment instead of a general 
protocol39. A recent study to assess the incidence of DVT in 
subjects undergoing arthroscopy for reconstruction of the 
ACL reported an incidence of DVT in 12% during the first 
week, higher than when the surgery is to repair other struc-
tures at the same time. In summary, the incidence increases 
by about 5% for every 30 min of tourniquet application. This 
means it is 5.6% if this time is < 90 min; 12.8% if between 90 
and 120 min, and 17.4% if this time exceeds 120 min40.
Consideration should also be given to the fact that par-
ticipating in any sport implies a certain degree of dehydra-
tion with the consequent increase of blood viscosity, espe-
cially if the athlete cannot, or does not know how to, 
hydrate themselves well, or there is very abundant fluid 
loss. It is not unusual for travel to take place soon after the 
competition. Planes or cars/coaches are vehicles that do 
not allow for walking for a certain period of time. National 
flights and bus travels usually last less than two hours, a 
more than reasonable time to stop and take a rest. Plane 
trips also have the inconvenience, apart from venous stasis, 
of being a place where there is a tendency to dehydration 
due to the low moisture content of the environment41. This 
aspect should be taken into consideration by athletes dur-
ing the flight. In regard to height and hydration, it is inter-
esting to note that sports performed at high altitude com-
bine several susceptibility factors, which in themselves 
have no great influence, but it is not known whether their 
combination creates an environment favourable to the 
presence of VTED, hypoxia, dehydration, haemoconcentra-
tion, low temperature, tight clothing, reduced mobility, 
age, previous long trip42. Any suspicious process should alert 
to an early diagnosis, and any subject with a history should 
assess their genetic susceptibility (Table 14).
Finally, it should be remembered that there are ergo-
genic substances such as anabolic steroids, growth hor-
mones, blood concentrate transfusions, the use of erythro-
poietin, etc.43 whose aim is to preserve the athlete’s health 
and guarantee clean competition but which are considered 
performance enhancing drugs and not expected to be 
found, but unfortunately they are not infrequent in various 
areas of physical work, almost always acquired illegally, 
and causing a kaleidoscope of serious diseases where VTED 
is highly present. If these conditions affect more predis-
posed or associated with certain activities individuals it 
should be studied, since there seems to be an alarming 
prevalence of presentation of pulmonary embolism in bas-
ketball47, with associated probability individual idiosyncra-
sies, this event does not occur or does very differently and 
less conspicuous in professional football48. In the first case, 
it is possible that the characteristics of sport than those 
that predispose and facilitate, but select subjects that have 
them and they are also the result of a lability to present 
VTE, where the sport environment makes them proof.
On trips of more or less 2* hours, it is necessary to make 
sure to: 
• Walk. When travelling by plane or train, walk for at 
least five minutes every hour along the aisles of the plane 
or carriage. When travelling by car or coach, stop every 
hour and take advantage of the opportunity to walk.
• If the sitting position must be maintained, an attempt 
should be made to activate the muscles. Bend the knees, 
move the feet, flex/stretch and rotate the ankles, press the 
feet progressively against the floor, alternating one, the 
other, and both at the same time.
• Avoid tight clothing, strong elastics and creases in areas 
of flexion (Evidence III).
• Drink liquid (non-alcoholic) often and regularly. Hy-
drate well (Evidence II-3).
On trips of more than 2* hours in addition to the above 
make sure to:
* Considering trips of about two hours is an empirical decision ba-
sed on the maximum duration of flights in Spain or even continental 
Europe. The majority of trips by coach may exceed this period, 
although not always reaching the limits of the regulations regar-
ding current driving times and rest periods, EC Regulation No. 
561/2006, “Breaks of at least 45 minutes should be taken after four 
and a half hours at the latest”.
Table 12 Evidence level considered to establish recom-
mendations in accordance with the United States Preventi-
ve Service Task Force (USPSTF)
I Evidence obtained from at least one 
well-designed randomized controlled trial
II-1 Evidence obtained from well-designed 
controlled trials without randomization
II-2 Evidence obtained from well-designed 
case-control and cohort studies, preferably 
from more than one centre or research 
group
II-3 Evidence obtained from multiple time 
series designs with or without the 
intervention. Dramatic results in 
uncontrolled trials might also be regarded 
as this type of evidence
III Opinions of respected authorities based on 
clinical experience, descriptive studies, or 
reports from expert committees
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• Walk > 5 minutes every hour (Evidence II-2).
• Bend the ankles and knees often (Evidence II-2).
• Occasionally raise the legs (above hip level) (Evidence 
II-2).
If there is a risk of venous thrombosis:
• Use progressive compression stockings (Evidence II-3).
• Take an oral anticoagulant under medical prescription.
• LMWH at preventive doses (Evidence I).
In summary, the recommendations are: be well hydrat-
ed, move often, and, if there is any susceptibility, use pro-
gressive compression stockings or even LMWH at preventive 
doses.
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